---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-24-000691"
form_type: "8-K"
ticker: "PTHS"
cik: "0001919246"
company_name: "Pelthos Therapeutics Inc."
filed_at: "2024-04-09T23:59:59+00:00"
generated_at: "2026-06-04T01:09:47.759354+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Chromocell updates on $6.6M IPO, pipeline progress, and liability reduction

## Summary
- Closed IPO Feb 21, 2024, gross proceeds ~$6.6M; all pre-IPO debt and Series A preferred converted.
- Removed ~$2.7M in liabilities via Series C preferred issuance and CEO compensation deferral.
- Lead candidate CC8464 completed Phase I (no euphoria, 4% rash incidence); slow dose escalation planned before Phase II.
- New eye pain program CT2000 launched; Dr. Simon Chandler hired; animal toxicity studies expected H2 2024.
- 10-K delayed due to IPO workload; expects filing within permitted 15-day extension.

## SEC filing metadata
- accession: 0001753926-24-000691
- form_type: 8-K
- ticker: PTHS
- cik: 0001919246
- company_name: Pelthos Therapeutics Inc.
- filed_at: 2024-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1919246/000175392624000691/0001753926-24-000691-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1919246/000175392624000691/g084169_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-24-000691
- JSON: https://secwatch.observer/filing/0001753926-24-000691.json
- Plain text: https://secwatch.observer/filing/0001753926-24-000691.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.